Annexin Pharmaceuticals AB (publ) (ANNX)
Free
No email, no account, no signup.
Pulling latest news for Annexin Pharmaceuticals AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
Nasdaq First North Growth Market
Type
Biotech
Sector
Biotechnology / Drug Development
Market Cap
$11M
We're already tracking Annexin Pharmaceuticals AB (publ) — here are the latest events we've registered
Recent News
- On May 7, 2026, the company announced that five patients have been treated in the ongoing Phase 2a NEXUS study for RVO and diabetic retinopathy. In April 2026, Annexin secured a SEK 4 million bridge loan and announced plans for a SEK 20 million rights issue to fund its clinical programs through the end of the year.
Want to know how this news affects Annexin Pharmaceuticals AB (publ)? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Annexin Pharmaceuticals AB (publ) will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.